Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Total Non-Current Liabilities (2016 - 2025)

Traws Pharma's Total Non-Current Liabilities history spans 12 years, with the latest figure at $11.1 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $11.1 million for Q4 2025, down 20.94% from a year ago — trailing twelve months through Dec 2025 was $11.1 million (down 20.94% YoY), and the annual figure for FY2025 was $11.1 million, down 20.94%.
  • Total Non-Current Liabilities for Q4 2025 was $11.1 million at Traws Pharma, up from $7.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $14.1 million in Q4 2024 to a low of $7.4 million in Q2 2025.
  • The 3-year median for Total Non-Current Liabilities is $11.1 million (2021), against an average of $10.8 million.
  • The sharpest move saw Total Non-Current Liabilities rose 4.84% in 2021, then fell 20.94% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $10.9 million in 2021, then increased by 29.88% to $14.1 million in 2024, then fell by 20.94% to $11.1 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $11.1 million, $7.9 million, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.